Full remission and relapse of obsessive-compulsive symptoms after cognitive-behavioral group therapy: A two-year follow-up

Revista Brasileira de Psiquiatria

Volumn 32, Issue 2, 2010, Pages 164-168

  Braga, Daniela Tusi ^a   Manfro, Gisele Gus ^b   Niederauer, Kátia ^a   Cordioli, Aristides Volpato ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cognitive therapy; Longitudinal studies; Obsessive compulsive disorder; Psychotherapy, group; Recurrence

Indexed keywords

ADULT; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; RATING SCALE; RELAPSE; REMISSION; SYMPTOMATOLOGY; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ANALYSIS OF VARIANCE; COGNITIVE THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY, GROUP; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958505897     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462010000200012     Document Type: Article

References (21)

1. Kennedy S. Full remission: a return to normal functioning. J Psychiatry Neurosci. 2002;27(4):233-4. (Pubitemid 34988902)
2. McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry. 2004;49(Suppl 1):10S-6S.
3. Kipper L, Blaya C, Wachleski C, Dornelles M, Salum GA, Heldt E, Manfro GG. Trauma and defense style as response predictors of pharmacological treatment in panic patients. Eur Psychiatry. 2007;22(2):87-1.
4. van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP. World Council of Anxiety WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003;8(8 Suppl 1):40-2.
5. Hollander E, Zohar J. Beyond refractory obsessions and anxiety states: toward remission. J Clin Psychiatry. 2004;65 Suppl 14:3-5.
6. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2004;65 Suppl 14:6-10.
7. Braga DT, Cordioli AV, Niederauer K, Manfro GG. Cognitive-behavioral group therapy for obsessive-compulsive disorder: a 1-year follow-up. Acta Psychiatr Scand. 2005;112(3):180-6. (Pubitemid 41176553)
8. Eisen Jl, Goodman WK, Keller MB, Warshaw MG, Lyne MD, Luce DD, Rasmussen SA. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 1999;60(5):346-1.
9. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S. Predictors of course in obsessive-compulsive disorder. Psychiatry Res. 1999;89(3):229-8.
10. Catapano F, Perris F, Masella M, Rossano F, Cigliano M, Magliano L, Maj M. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. J Psychiatr Res. 2006;40(6):502-10. (Pubitemid 44175407)
11. Pato, MT, Zohar, KM, Zohar, R. Return of symptoms after discontinuation of clorimipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145(12):521-5.
12. Volpato Cordioli A, Heldt E, Braga Bochi D, Margis R, Basso Souza M, Tonello J, Gus Manfro G, Kapczinski F. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychother Psychosom. 2003;72(4):211-6.
13. Goodman WK, Price LH, Rasmussen AS, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS.The Yale-Brown Obsessive-Compulsive Scale: I development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-16.
14. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976. p.218-2.
15. Cunha JA. Manual da versão em português das escalas de Beck. São Paulo (SP): Casa do Psicólogo; 2001.
16. van Oppen P, van Balkom AJ, de Haan E, van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5 year follow-up. J Clin Psychiatry. 2005;66(11):1415-22.
17. Rufer M, Hand I, Alsleben H, Braatz A, Ortmann J, Katenkamp B, Fricke S, Peter H. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):121-8.
18. Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(7):1133-9.
19. Gava I, Barbui C, Aguglia E, Carlino D, Churchill R, De Vanna M, McGuire HF. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2007;18(2):CD005333.
20. Kapman M, Keijsers GP, Hoogduin CA, Verbraak MJ. Addition of CBT for OCD patients non-responding to fluoxetine. Acta Psychiatr Scand. 2002;106(4):314-9.
21. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151-1.